The case of chronic myeloid leukemia in a child of 2 years
https://doi.org/10.17650/2311-1267-2017-4-3-64-66
Abstract
Chronic myeloid leukemia (CML) is a rare disease in childhood. Long-term use of tyrosine kinase inhibitors has become the standard for the treatment of the chronic phase of CML. The article describes the case of development of CML in a child at the age of two years and raised the issue of the need for lifelong drug intake and the problems that arise in connection with this.
About the Authors
E. V. Yakupova
Republican Children’s Clinical Hospital
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
T. N. Krasavtseva
Republican Children’s Clinical Hospital
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
E. F. Amirova
Republican Children’s Clinical Hospital
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
A. I. Makhonina
Republican Children’s Clinical Hospital
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
Russian Federation
98 Stepana Kuvykina St., Ufa, 450106, Republic of Bashkortostan, Russia
References
1. Krumbholz M., Karl M., Tauer J.T. et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer 2012;51(11):1045–53. doi: 10.1002/gcc.21989.
2. Karalexi M.A., Baka M., Ryzhov A. et al. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. Eur J Cancer 2016;67:183–90. doi: 10.1016/j. ejca.2016.08.011.
3. Hanfstein B., Lauseker M., Hehlmann R. et al.; SAKK and the German CML Study Group. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 2014;99(9):1441–7. doi: 10.3324/haematol.2013.096537.
4. Hijiya N., Schultz K.R., Metzler M., Millot F., Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 2016;127(4):392–9. doi: 10.1182/blood-2015-06-648667.
5. Румянцев А.Г., Масчан А.А., Жуковская Е.В. и др. Детская гематология. Сборник клинических рекомендаций. М.: ГЭОТАР-Медиа, 2015. [Rumyantsev A.G., Maschan A.A., Zhukovskaya E.V. Pediatric Hematology. Collection of clinical guidelines. M.: GEOTAR-Media, 2015. (In Russ.)].
6. Tanizawa A. Optimal management for pediatric chronic myeloid leukemia. Pediatr Int 2016;58(3):171–9. doi: 10.1111/ped.12876.
7. Zhang G.F., Zhou M., Bao X.B. et al. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia. Asian Pac J Cancer Prev 2016;17(9):4477– 81. PMID: 27797264.
Review
For citations:
Yakupova E.V., Krasavtseva T.N., Amirova E.F., Makhonina A.I. The case of chronic myeloid leukemia in a child of 2 years. Russian Journal of Pediatric Hematology and Oncology. 2017;4(3):64-66. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-3-64-66
Views:
712
Email this article 